Kartos Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.kartosthera.com
Clinical Trials
74
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (74 trials with phase data)• Click on a phase to view related trials
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
- Conditions
- MyelofibrosisPost-ET MyelofibrosisPrimary MyelofibrosisPost-PV MFMF
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT06479135
- Locations
- 🇺🇸
UAB Hospital, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Mayo Clinic - Phoenix, Phoenix, Arizona, United States
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Conditions
- Endometrial Cancer
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 268
- Registration Number
- NCT05797831
- Locations
- 🇺🇸
Kaiser Permanente Center, Vallejo, California, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
🇺🇸St. Joseph, Savannah, Georgia, United States
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Registration Number
- NCT05705466
KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer
- Conditions
- Small-cell Lung CancerSmall Cell Lung CarcinomaSmall Cell Lung Cancer Extensive StageSmall Cell Lung Cancer Recurrent
- Interventions
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT05027867
- Locations
- 🇺🇸
Florida Cancer Specialists - 3840 Broadway, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists - 560 Jackson St, Suite 220, Saint Petersburg, Florida, United States
🇺🇸Florida Cancer Specialists, West Palm Beach, Florida, United States
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
- Conditions
- Primary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Kartos Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT04878003
- Locations
- 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- Next